CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
NCT Number: NCT05032261
Norepinephrine is recommended as first-line vasopressor in critically ill patients, regardless of shock etiology. Its advantages over dopamine and/or epinephrine have been demonstrated, especially by reducing tachycardia events. The current guidelines recommend a mean arterial pressure of at least 65 mmHg that in the resuscitation from sepsis-induced hypoperfusion. Some study reported that delay in initiation of vasopressor therapy was associated with an increase mortality risk in patient with septic shock .The recent experts' opinion suggest that " vasopressors should be started early, before (complete) completion of fluid ressuscitation ".
In the event of refractory septic shock, high-dose vasopressors may be used. The precise maximal dose of norepinephrine associated with mortality excess has been poorly studied. High doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%. Furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock septic was associated with increased mortality depending of fluid administration. If a threshold value of norepinephrine score can be obtained, it could indicate the association with another vasopressor such as vasopressin or surrogates.
The primary aim of the present study aimed to confirm if a given norepinephrine dose is associated with mortality. The secondary aims were the link between mortality and norepinephrine duration, cumulative dose in order to build a score that predicts a futility of increasing norepinephrine dose.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Nîmes, 30029, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient without norepinephrine or missing data.
Circulatory shock with norepinephrine in ICU
Time frame: Day 5
Mortality within 5 days of the date of ICU admission for circulatory shock according to norepinephrine intensity
Time frame: Day 5
Intensity mortality relationship according to norepinephrine duration
Time frame: Day 5
ratio between time of use and cumulative dose
Time frame: Day 5
score of increasing norepinephrine dose
Centre Hospitalier Universitaire de Nīmes
Other
Norepinephrine Load and Relationship With Prognosis in Critically Patients With Circulatory Shock
Acronym: ICU_NE_LOAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT02728791
Cardiac Output, Low, Cardiovascular Diseases
Brest, France
View Trial DetailsNCT07411976
Critical Illness, Disease Attributes
Nîmes, France
View Trial DetailsNCT02476253
Acid-Base Imbalance, Acidosis
Montpellier, France
View Trial Details